2018 Fiscal Year Final Research Report
Development of the novel therapy for renal cell carcinoma resistance to molecular targeting therapy using the assessment by FDG PET/CT
| Project/Area Number |
16K11021
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
矢尾 正祐 横浜市立大学, 医学研究科, 教授 (00260787)
近藤 慶一 横浜市立大学, 附属病院, 准教授 (80363836)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Keywords | 腎細胞癌 / 分子標的治療薬 / 抵抗性獲得機序 / ブドウ糖集積 / FDG PET/CT |
|---|
| Outline of Final Research Achievements |
We identified the candidates of the blood biomarker which assess the anti-tumor effect of tyrosine kinase inhibitor for vascular endothelial growth factor receptor (VEGFr-TKI) to renal cell carcinoma (RCC) in real time, using the blood samples gained from the patients who were monitored by FDG PET/CT. This biomarker could predict not only the progression free survival of VEGFr-TKI, but also the response to mTOR inhibitor of RCC. Based on the sequential FDG PET/CT monitoring of RCC treated by VEGFr-TKI, we clarified the resistance acquisition mechanism of RCC to VEGFr-TKI which was regulated by mTOR protein signal. Additionally, we revealed that the early assessment using FDG PET/CT was useful for predicting the anti-tumor effect of immune checkpoint inhibitor to RCC.
|
| Free Research Field |
泌尿器悪性腫瘍
|
| Academic Significance and Societal Importance of the Research Achievements |
病態を評価する血液バイオマーカーが確立されていない腎細胞癌において腫瘍径の著明な変化を来さずに抗腫瘍効果を発揮することのある血管新生阻害剤、mTOR阻害剤、免疫チェックポイント阻害剤の効果判定は従来のCT画像評価だけでは困難であり、治療の切り替えのタイミングが臨床上大きな課題となっている。我々が同定した血液バイオマーカーとFDG PET/CTによって治療中の腎細胞癌をモニタリングすることにより効率の高い治療体系を確立できれば、進行性腎細胞癌患者さんの生命予後の延長が期待できるだけでなく、無効な治療を継続することで生じる副作用による生活の質の低下や医療費の高騰を防ぐことが可能と思われた。
|
